Navigation Links
Catalent Biologics Launches GPEx® Boost Cell Line Expression Technology to Improve Titers and Cell-Specific Productivity
Date:11/5/2019

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced the launch of its next-generation cell line development technology, GPEx® Boost. The technology enhances Catalent’s proven GPEx expression platform through multiple improvements, including utilization of a glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line. The combination of technology and platform enhancements has resulted in improved ability of cells to produce high titers and increase specific productivities of a protein of interest.

GPEx Boost has been shown to improve titers up to four-fold, potentially to 10 g/L for standard monoclonal antibodies, while maintaining the stability benefits offered by the traditional GPEx platform. In addition, benefits have been observed in cell growth and viability. Developmental timelines for projects can be shortened and made more efficient by combining this new platform with the rapid screening capabilities of Berkeley Lights’ Beacon® optofluidic platform, and ambr® automated micro bioreactors.

“GPEx Boost technology builds on the proven GPEx platform to enable significantly higher productivity and stability for even the most difficult-to-express proteins,” commented Michael Riley, President, USA Region of Catalent Biologics. “This new proprietary platform can also be combined with other state-of-the-art technology, such as the Beacon system, to provide a unique development tool for our customers.”

Catalent’s proprietary GPEx technology creates stable, high-yielding mammalian cell lines with high speed and efficiency. The advantages of applying GPEx technology span from early feasibility studies to clinical manufacturing, through to commercial scale production. To date, 12 biopharmaceutical drugs produced using GPEx technology have been approved and marketed, with more than 120 ongoing clinical trials utilizing therapeutic candidates developed using the GPEx platform.

For more information, please visit http://www.catalent.com/gpex

About Catalent Biologics
For more than two decades, Catalent Biologics has built capabilities and experience in development, manufacturing, and analytical services for new biological entities, gene therapies, biosimilars, and antibody-drug conjugates. Catalent has worked with 600+ mAbs and 80+ proteins, and 12 biopharmaceutical drugs produced using GPEx® cell line development technology have been approved and marketed, with more than 120 ongoing clinical trials utilizing therapeutic candidates developed using the GPEx® platform. A further 25 commercially-approved products have employed Catalent Biologics’ capabilities through to aseptic fill/finish. Catalent’s latest addition, Paragon Gene Therapy, provides industry-leading capabilities and expertise in the development and manufacturing of adeno-associated virus (AAV) vectors, next-generation vaccines and oncolytic virus production. Its manufacturing facilities in Baltimore, Maryland have produced over 100 GMP batches across 40 clinical and commercial programs. Using advanced technology and tailored solutions for clinical through commercial supply, Catalent Biologics brings better biologic treatments to patients, faster.
For more information on Catalent Biologics, visit http://www.catalent.com/biologics.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/catalent_biologics_launches_gpex_boost_cell_line_expression_technology_to_improve_titers_and_cell_specific_productivity/prweb16695526.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Portages Biohaven enters into exclusive formulation agreement and global license with Catalent for lead product
2. Catalent Executives to Present on Clinical Trial Supply Management and Optimizing Product Development at Upcoming BioPharma Asia Conference
3. Catalent Biologics Announces Collaboration with Therachon, Switzerland, to Advance Clinical Development of Innovative Protein Therapy for Achondroplasia
4. Lipid-Based Drug Delivery in Modern Pharmaceutical Development to be Presented by Catalent and BASF at Forthcoming Workshop
5. Patient-Focused Drug Delivery to be Presented by Catalent at PODD
6. IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases
7. Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy
8. Catalent Expert to Discuss the Importance of Formulation to Benefit Diabetes Patients at NLS Days
9. Flexible Filling and Adoption of ‘Ready-to-Use’ Technologies to be Discussed by Catalent Biologics at the Pharma Forum
10. Advantages of Singapore as a Clinical Supply Hub to be Discussed by Catalent at Accelerating Clinical Trials in Asia Conference
11. Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/10/2020)... ... January 09, 2020 , ... ... services, today announced the acquisition of Cunesoft, a move that expands the company’s ... objectives of life sciences companies. , Based in Munich, Germany, Cunesoft provides intelligent ...
(Date:1/8/2020)... ... January 08, 2020 , ... ... can achieve specific properties for use in harsh environments inside or outside of ... up to three metals or alloys to achieve specific properties such as corrosion-resistance, ...
(Date:1/7/2020)... , ... January 07, 2020 , ... ... products and services, today announced the launch of its VivopureX™ recombinant mouse antibodies ... clones, many originally obtained from rats or hamsters, which Absolute Antibody has engineered ...
(Date:1/7/2020)... ... January 06, 2020 , ... EconoFact, a non-profit ... Fletcher School at Tufts University, is pleased to announce that it was awarded ... administered by Tufts University, and will help to expand the scope, exposure and ...
Breaking Biology Technology:
(Date:12/4/2019)... ... December 03, 2019 , ... Genedata, the ... Agenus , a clinical-stage immuno-oncology company developing therapies to fight cancer, has chosen ... Agenus will use the platform to support immunotherapy and vaccine pipeline programs across ...
(Date:12/2/2019)... ... December 01, 2019 , ... Each year The ... to hit the life-science landscape. For more than a decade, our expert panels ... and facilitating biological discovery. This year’s crop of entries to The Scientist’s Top ...
(Date:11/27/2019)... ... 2019 , ... The MyOnyx rehab solution by ... that measure and display muscle activity in real time. This information helps the ... Both patient and therapist can see when exercises are performed correctly and efficiently. ...
Breaking Biology News(10 mins):